C

폴라리스AI파마

041910KOSDAQ의약품 제조업

47.1 / 100

Reference Date: 2026-04-13

Financial Score17.0 / 40
News Sentiment16.1 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but Revenue is on a declining trend. Plunged 15.9% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Polaris AI Pharma primarily operates in API (Active Pharmaceutical Ingredient) and CDMO (Contract Development and Manufacturing Organization) sectors, with API contributing 96.3% of its 2025 revenue. The company focuses on expanding high-value CDMO services while maintaining strong collaborations with domestic and international pharmaceutical firms, particularly emphasizing exports to the demanding Japanese market.

Number of Employees

167people

Average Salary

51.6M KRW

Score Calculation Basis

Detailed Financial Score

PER
14.85Industry Average 14.803.0Point

Higher than industry avg (caution)

PBR
0.68Industry Average 1.045.5Point

Lower than industry avg (good)

ROE
4.66Industry Average 4.424.0Point

In line with industry avg

Debt Ratio
22.92Industry Average 11.980.5Point

1.9x industry avg (risky)

Trend 2023~20254.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼7.0% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲807.7% (2-year basis)

ROE Trend
1.0 / 4

Avg ROE 3.7% (improving, 3yr)

Detailed News Sentiment

7 totalPositive 3Neutral 1Negative 0Average Sentiment Score 75

Detailed Momentum

52-week position3.0Point

52w lower range (34%)

Current 6,890Won52-week high 9,17052-week low 5,670
1-month return0.0Point

1m -15.87% (strong drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

7 totalPositive 0Neutral 7Negative 0
  • Neutral증권발행결과(자율공시)2026-03-26
  • Neutral[기재정정]주요사항보고서(전환사채권발행결정)2026-03-26
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-24
  • Neutral정기주주총회결과2026-03-23
  • Neutral대표이사변경2026-03-23